Skip to search formSkip to main contentSkip to account menu

PDGFR alpha/KIT Mutant-specific Inhibitor BLU-285

Known as: BLU-285 
An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Systemic mastocytosis (SM) has greatly benefited from the broad application of precision medicine techniques to hematolymphoid… 
2019
2019
The frequent occurrence of multidrug resistance (MDR) conferred by the overexpression of ATP-binding cassette (ABC) transporters… 
Review
2018
Review
2018
Gastrointestinal stromal tumors (GISTs) originate from interstitial cells of Cajal and account for over 5,000 newly diagnosed… 
Highly Cited
2017
Highly Cited
2017
BLU-285 is a selective and potent mutant KIT and PDGFRA inhibitor active in both preclinical and clinical settings. Treatment… 
2017
2017
  • Cancer discovery
  • 2017
  • Corpus ID: 12802010
Tyrosine kinase inhibitors may initially control gastrointestinal stromal tumors, but most patients eventually experience disease… 
2017
2017
Background: The KIT D816V mutant is a key oncogenic driver found in ~90% of AdvSM, a group of poor prognosis mast cell (MC… 
2017
2017
11011Background: Oncogenic mutations in KIT or PDGFRα drive > 85% of GIST. However, primary and acquired mutations in the… 
Review
2016
Review
2016
Background: Aggressive Systemic Mastocytosis (ASM) and the related disorders, SM with associated hematologic non-mast cell… 
2015
2015
The advent of imatinib therapy in gastrointestinal stromal tumor (GIST) has been transformative, altering the treatment of…